Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

GB:0RU5 Stock Latest News

Company AnnouncementsOncoinvent bolsters Radspherin programme with Phase 2 progress and NOK 148.5m raise4d ago

Company AnnouncementsOncoinvent sets investor webcast as it advances radiopharmaceutical cancer therapy1w ago
Company AnnouncementsOncoinvent Cancels Planned Subsequent Share Offering After Price Slump3w ago
Company AnnouncementsOncoinvent Completes Private Placement as Linc AB Stake Rises to 12.21%1M ago
Company AnnouncementsHadean Ventures Funds Lift Oncoinvent Stake to Over 12% After Private Placement1M ago

Oncoinvent Registers Share Capital Increase After Private Placement

Company AnnouncementsOncoinvent Registers Share Capital Increase After Private Placement1M ago

Company AnnouncementsOncoinvent’s Radspherin Program Gains Spotlight at EANM and ESMO 20261M ago

Company AnnouncementsOncoinvent Details Insider Allocation in Retail Share Offering1M ago

Company AnnouncementsOncoinvent Shares Begin Trading Ex-Rights Ahead of Planned Offering1M ago
Company AnnouncementsHadean Ventures Funds Adjust Oncoinvent Stake Amid Private Placement Settlement1M ago
Company AnnouncementsOncoinvent Publishes Insider Allocation Details from Recent Private Placement1M ago
Company AnnouncementsOncoinvent Sets Terms for Conditional Repair Offering After Private Placement1M ago

Oncoinvent Raises NOK 148.5 Million to Advance Radspherin Into Late-Stage Trials

Company AnnouncementsOncoinvent Raises NOK 148.5 Million to Advance Radspherin Into Late-Stage Trials1M ago

Company AnnouncementsOncoinvent Seeks NOK 140 Million to Bolster Ovarian Cancer Trial and Phase 3 Plans1M ago

Company AnnouncementsOncoinvent Asa Earnings Call Highlights Trial Momentum2M ago

Company AnnouncementsOncoinvent advances Radspherin trials and IP as losses widen in first half 20262M ago
Company AnnouncementsOncoinvent Sets August Webcast as Radspherin Advances Toward Post-Surgical Cancer Standard2M ago
Company AnnouncementsOncoinvent’s Radspherin Shows Favorable Dosimetry in Phase 1 Cancer Studies2M ago
Company AnnouncementsOncoinvent Hits 50% Enrollment in Phase 2 Radspherin Trial for Ovarian Cancer4M ago

Company AnnouncementsOncoinvent Aligns Board Incentives with Equity Grants as Radspherin Advances5M ago

Company AnnouncementsOncoinvent Clears AGM Agenda as It Pushes Radspherin Toward Post-Surgical Cancer Market5M ago

Company AnnouncementsOncoinvent Finalizes Major Share Capital Reduction Amid Progress on Cancer Therapy Radspherin6M ago